Rectal large cell neuroendocrine carcinoma.

IF 0.4 Q3 MEDICINE, GENERAL & INTERNAL

Oxford Medical Case Reports Pub Date : 2025-09-28 eCollection Date: 2025-09-01 DOI:10.1093/omcr/omaf185

Panagiotis Alexandros Drakos, Antonia A Prountzopoulou, Efrossini Totskas, Konstantinos Stamou

{"title":"Rectal large cell neuroendocrine carcinoma.","authors":"Panagiotis Alexandros Drakos, Antonia A Prountzopoulou, Efrossini Totskas, Konstantinos Stamou","doi":"10.1093/omcr/omaf185","DOIUrl":null,"url":null,"abstract":"<p><p>Rectal large cell neuroendocrine carcinoma (LCNEC) is an exceedingly rare and aggressive neoplasm with a poor prognosis and median survival of 4-16 months. Diagnosis is challenging due to the clinical overlap with classical colorectal adenocarcinoma, and accurate diagnosis is reliant on histological examination via immunohistochemistry (IHC). For the diagnosis of LCNEC, neuroendocrine markers such as Synaptophysin, CD56, chromogranin A and Ki-67 are major determinants of the disease. We present a double case report of two individuals initially assumed diagnosed as rectal adenocarcinoma who were then re-diagnosed with rectal LCNEC via post-surgical IHC. Both patients received neo-adjuvant chemotherapy yet still developed metastatic disease. This report intends to appraise the role of routine early IHC as a critical tool for diagnosis and to guide management planning. Given the rarity and volatility of rectal LCNEC, further research is desperately needed to develop tailored treatment measures and improve patient outcomes.</p>","PeriodicalId":45318,"journal":{"name":"Oxford Medical Case Reports","volume":"2025 9","pages":"omaf185"},"PeriodicalIF":0.4000,"publicationDate":"2025-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12476556/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oxford Medical Case Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1093/omcr/omaf185","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/9/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Rectal large cell neuroendocrine carcinoma (LCNEC) is an exceedingly rare and aggressive neoplasm with a poor prognosis and median survival of 4-16 months. Diagnosis is challenging due to the clinical overlap with classical colorectal adenocarcinoma, and accurate diagnosis is reliant on histological examination via immunohistochemistry (IHC). For the diagnosis of LCNEC, neuroendocrine markers such as Synaptophysin, CD56, chromogranin A and Ki-67 are major determinants of the disease. We present a double case report of two individuals initially assumed diagnosed as rectal adenocarcinoma who were then re-diagnosed with rectal LCNEC via post-surgical IHC. Both patients received neo-adjuvant chemotherapy yet still developed metastatic disease. This report intends to appraise the role of routine early IHC as a critical tool for diagnosis and to guide management planning. Given the rarity and volatility of rectal LCNEC, further research is desperately needed to develop tailored treatment measures and improve patient outcomes.

查看原文本刊更多论文

直肠大细胞神经内分泌癌。

直肠大细胞神经内分泌癌（LCNEC）是一种非常罕见的侵袭性肿瘤，预后差，中位生存期为4-16个月。由于与经典结直肠癌的临床重叠，诊断具有挑战性，准确诊断依赖于免疫组织化学（IHC）的组织学检查。对于LCNEC的诊断，神经内分泌标志物如Synaptophysin、CD56、chromogranin A和Ki-67是该疾病的主要决定因素。我们提出了一个双病例报告，两个人最初被诊断为直肠腺癌，然后通过术后免疫组化重新诊断为直肠LCNEC。两例患者均接受了新辅助化疗，但仍发生转移性疾病。本报告旨在评价常规早期免疫健康检查作为诊断和指导管理规划的关键工具的作用。鉴于直肠LCNEC的罕见性和波动性，迫切需要进一步的研究来制定量身定制的治疗措施并改善患者的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Oxford Medical Case Reports MEDICINE, GENERAL & INTERNAL-

CiteScore

0.90

自引率

0.00%

发文量

125

审稿时长

19 weeks

期刊介绍： Oxford Medical Case Reports (OMCR) is an open access, peer-reviewed online journal publishing original and educationally valuable case reports that expand the field of medicine. The journal covers all medical specialities including cardiology, rheumatology, nephrology, oncology, neurology, and reproduction, comprising a comprehensive resource for physicians in all fields and at all stages of training. Oxford Medical Case Reports deposits all articles in PubMed Central (PMC). Physicians and researchers can find your work through PubMed , helping you reach the widest possible audience. The journal is also indexed in the Web of Science Core Collection . Oxford Medical Case Reports publishes case reports under the following categories: Allergy Audiovestibular medicine Cardiology and cardiovascular systems Critical care medicine Dermatology Emergency medicine Endocrinology and metabolism Gastroenterology and hepatology Geriatrics and gerontology Haematology Immunology Infectious diseases and tropical medicine Medical disorders in pregnancy Medical ophthalmology Nephrology Neurology Oncology Paediatrics Pain Palliative medicine Pharmacology and pharmacy Psychiatry Radiology, nuclear medicine, and medical imaging Respiratory disorders Rheumatology Sexual and reproductive health Sports Medicine Substance abuse.